BERKELEY, CA--(Marketwire - September 16, 2010) - Dynavax Technologies Corporation (
Mr. Ostrach will present a corporate overview, which will be webcast. To access the live webcast and the subsequent archived recording of the presentation, please log onto Dynavax's website at http://investors.dynavax.com/newsevents.cfm.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV™, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.
Contact Information:
Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257